FORT LEE, N.J., April 29, 2024 /PRNewswire/ -- Kedrion Biopharma Inc., an international biopharmaceutical company specializing in the research and development, production, and commercialization of plasma-derived therapeutic products used in treating rare and serious diseases, announced today that plasminogen deficiency type 1 (PLGD-1) patients in the U.S. now have access to RYPLAZIM® (plasminogen, human-tvmh).
Results from pivotal phase 2/3 study met co-primary endpoints for improvement in trough plasminogen activity levels and reduction in lesion size
LAVAL, QC and CAMBRIDGE, United Kingdom, May 22, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced the presentation of three scientific posters on the Company's lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™ (plasminogen), on lung fibrosis indications, at the American Thoracic Society (ATS) 2019 International Conference taking place in Dallas, Texas, from May 17 – 22, 2019.